Reovirus as an oncolytic agent against experimental human malignant gliomas

Journal of the National Cancer Institute

Volumn 93, Issue 12, 2001, Pages 903-912

  Wilcox, M Elizabeth ^a   Yang, WenQing ^a   Senger, Donna ^a   Rewcastle, N Barry ^b   Morris, Donald G ^c   Brasher, Penny M A ^c   Shi, Z Qiao ^a   Johnston, Randal N ^a   Nishikawa, Sandi ^a   Lee, P W K ^a   Forsyth, Peter A ^a,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b FOOTHILLS HOSPITAL   (Canada)

^c TOM BAKER CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; ONCOLYTIC VIRUS; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL DIVISION; CELL KILLING; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; INFECTION; MALE; MALIGNANT MENINGIOMA; MOUSE; MUSCLE NECROSIS; NONHUMAN; PRIORITY JOURNAL; REOVIRUS; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR NECROSIS; TUMOR REGRESSION; WEIGHT GAIN;

EID: 0035918857     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.12.903     Document Type: Article

References (33)

1. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study
2. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin
3. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop
4. Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells
5. Amplification of the epidermal growth factor receptor gene in biopsy specimens from human intracranial tumours
6. Reovirus therapy of tumors with activated Ras pathway
7. Ras activation in astrocytomas and neurofibromas
8. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene
9. Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: Implications for autologous vaccine production
10. Combination gene therapy for liver metastasis of colon carcinoma in vivo
11. Prevention of hepatic tumor metastases in rats with herpes viral vaccines and γ-interferon
12. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
13. Experimental therapy of human glioma by means of a genetically engineered virus mutant
14. Newcastle disease virus (NDV): Brief history of its oncolytic strains
15. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
16. Intergeneric poliovirus recombinants for the treatment of malignant glioma
17. Reoviruses
18. Reoviruses
19. Lymphocytes protect against and are not required for reovirus-induced myocarditis
20. Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency
21. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection
22. The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus
23. Polypeptide components of virions, top component and cores of reovirus type 3
24. Protein sigma 1 is the reovirus cell attachment protein
25. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
26. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
27. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: A phase I trial
28. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector
29. Gene transfer technologies for malignant gliomas
30. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy
31. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
32. Inflammatory thoughts about glioma gene therapy
33. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials